Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer During Neoadjuvant Chemoradiation

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Jan 20

PMID 38245646

Authors

Xin Xiao

Pin-Hao Fang

Jian-Feng Zhou

Xiao-Kun Li

Qi-Xin Shang

Yu-Shang Yang

Si-Yuan Luan

Long-Qi Chen

Yong Yuan

Affiliations

Soon will be listed here.

Abstract

Background: The impact of changes in skeletal muscle and sarcopenia on outcomes during neoadjuvant chemoradiotherapy (NACR) for patients with esophageal cancer remains controversial.

Patients And Methods: We retrospectively analyzed the data of patients with locally advanced esophageal squamous cell cancer who received NACR followed by esophagectomy between June 2013 and December 2021. The images at third lumbar vertebra were analyzed to measure the cross-sectional area and calculate skeletal muscle index (SMI) before and after NACR. SMI less than 52.4 cm/m for men and less than 38.5 cm/m for women were defined as sarcopenia. The nonlinearity of the effect of percent changes in SMI (ΔSMI%) to survival outcomes was assessed by restricted cubic splines.

Results: Overall, data of 367 patients were analyzed. The survival outcomes between sarcopenia and non-sarcopenia groups had no significant differences before NACR. However, patients in post-NACR sarcopenia group showed poor overall survival (OS) benefit (P = 0.016) and poor disease-free survival (DFS) (P = 0.043). Severe postoperative complication rates were 11.9% in post-NACR sarcopenia group and 5.0% in post-NACR non-sarcopenia group (P = 0.019). There was a significant non-linear relationship between ΔSMI% and survival outcomes (P < 0.05 for non-linear). On the multivariable analysis of OS, ΔSMI% > 12% was the independent prognostic factor (HR 1.76, 95% CI 1.03-2.99, P = 0.039) and significant difference was also found on DFS analysis (P = 0.025).

Conclusions: Patients with post-neoadjuvant chemoradiotherapy sarcopenia have worse survival and adverse short-term outcomes. Moreover, greater loss in SMI is associated with increased risks of death and disease progression during neoadjuvant chemoradiotherapy, with maximum impact noted with SMI loss greater than 12%.

References

Li X, Chen L, Luan S, Zhou J, Xiao X, Yang Y . The development and progress of nanomedicine for esophageal cancer diagnosis and treatment. Semin Cancer Biol. 2022; 86(Pt 2):873-885. DOI: 10.1016/j.semcancer.2022.01.007. View

Ajani J, DAmico T, Bentrem D, Chao J, Corvera C, Das P . Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(7):855-883. DOI: 10.6004/jnccn.2019.0033. View

Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Takahashi K . The Impact of Pretherapeutic Naples Prognostic Score on Survival in Patients with Locally Advanced Esophageal Cancer. Ann Surg Oncol. 2021; 28(8):4530-4539. DOI: 10.1245/s10434-020-09549-5. View

Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M . Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2015; 23(2):646-54. DOI: 10.1245/s10434-015-4869-5. View

McGovern J, Dolan R, Horgan P, Laird B, McMillan D . Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 2021; 12(6):1408-1417. PMC: 8718024. DOI: 10.1002/jcsm.12831. View

Jogiat U, Sasewich H, Turner S, Baracos V, Eurich D, Filafilo H . Sarcopenia Determined by Skeletal Muscle Index Predicts Overall Survival, Disease-free Survival, and Postoperative Complications in Resectable Esophageal Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2022; 276(5):e311-e318. DOI: 10.1097/SLA.0000000000005452. View

Ishida T, Makino T, Yamasaki M, Yamashita K, Tanaka K, Saito T . Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021; 28(12):7185-7195. DOI: 10.1245/s10434-021-10025-x. View

Elliott J, Doyle S, Murphy C, King S, Guinan E, Beddy P . Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer. Ann Surg. 2017; 266(5):822-830. DOI: 10.1097/SLA.0000000000002398. View

Nakashima Y, Saeki H, Nakanishi R, Sugiyama M, Kurashige J, Oki E . Assessment of Sarcopenia as a Predictor of Poor Outcomes After Esophagectomy in Elderly Patients With Esophageal Cancer. Ann Surg. 2017; 267(6):1100-1104. DOI: 10.1097/SLA.0000000000002252. View

10.

Saeki H, Nakashima Y, Kudou K, Sasaki S, Jogo T, Hirose K . Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?. World J Surg. 2018; 42(9):2894-2901. DOI: 10.1007/s00268-018-4554-5. View

11.

Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A . Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol. 2016; 43(2):478-484. DOI: 10.1016/j.ejso.2016.11.015. View

12.

Huang C, Lue K, Hsieh T, Liu S, Wang T, Peng T . Association Between Sarcopenia and Clinical Outcomes in Patients With Esophageal Cancer Under Neoadjuvant Therapy. Anticancer Res. 2020; 40(2):1175-1181. DOI: 10.21873/anticanres.14060. View

13.

Reisinger K, Bosmans J, Uittenbogaart M, Alsoumali A, Poeze M, Sosef M . Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery. Ann Surg Oncol. 2015; 22(13):4445-52. PMC: 4644199. DOI: 10.1245/s10434-015-4558-4. View

14.

Kamitani N, Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H . Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy. Surg Today. 2019; 49(12):1022-1028. DOI: 10.1007/s00595-019-01846-1. View

15.

Jarvinen T, Ilonen I, Kauppi J, Salo J, Rasanen J . Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2018; 16(1):27. PMC: 5809976. DOI: 10.1186/s12957-018-1327-4. View

16.

Mayanagi S, Tsubosa Y, Omae K, Niihara M, Uchida T, Tsushima T . Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. Ann Surg Oncol. 2017; 24(12):3741-3747. PMC: 5658455. DOI: 10.1245/s10434-017-6020-2. View

17.

Liu J, Motoyama S, Sato Y, Wakita A, Kawakita Y, Saito H . Decreased Skeletal Muscle Mass After Neoadjuvant Therapy Correlates with Poor Prognosis in Patients with Esophageal Cancer. Anticancer Res. 2016; 36(12):6677-6685. DOI: 10.21873/anticanres.11278. View

18.

Prado C, Lieffers J, McCargar L, Reiman T, Sawyer M, Martin L . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629-35. DOI: 10.1016/S1470-2045(08)70153-0. View

19.

Mourtzakis M, Prado C, Lieffers J, Reiman T, McCargar L, Baracos V . A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997-1006. DOI: 10.1139/H08-075. View

20.

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View